Join Our Mailing List
Email:

News

Abstract Submission is now Open

Conference and Hotel Registrations

NEW! NLN Research Site

NLN Position Papers: Risk Reduction, Diagnosis and Treatment, Exercise, Air Travel, Training, Breast Cancer Screening

Recent Featured Lymph e-Channel

Financial Assistance for Garments

The Lymphedema Treatment Act

Support HR 2499

Clinical Trials - Patient Participation

Lymph Science Advocacy Program (LSAP)
A Training Program for Patient and Advocates at the 10th NLN Conference

The NLN Scientific Conference Committee is pleased to organize the 7th Lymph Science Advocacy Program (LSAP) during the 10th NLN International Conference - Research RoundUp. This is a unique program for lymphedema patients and advocates. The program is limited to 5 new participants, who will be selected from submitted applications, and who represent a diversity of backgrounds and interest; presently we have 20 LSAP graduates.

The goal of the LSAP Program is to engage and motivate patients and caregivers to action by providing a comprehensive understanding of basic science of the lymphatic system, as well as clinical and diagnostic research of patients living with lymphedema and related disorders.

Program Highlights:

Who can participate?

Patients affected with LE, advocates, caregivers, family members or those whose lives have been affected by lymphedema may apply. Applicants must show a curiosity and interest in learning scientific principles and research methods and be able to function as an observer in scientific session.

LSAP Application

For more information about the LSAP and to apply for the program, simply download the application here.

LSAP Alumni

Conference Reviews

Photos

2002
2006
2008
2010

| Top of Page |

About Us | Privacy Policy | Contact Us

©2011 National Lymphedema Network. All rights reserved.
Permission to print and duplicate this page for personal and educational purposes only, not for sale. Reprint Permission Request Form (pdf format, 86kb). For more information, call 415-908-3681.